Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A Prospective Open-Label Study
In the register
The register attaches this trial to Baricitinib (Olumiant) (Eli Lilly), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 2
- Sponsor
- National Taiwan University Hospital
- Participants (registry)
- 30
- Start
- January 2025 (planned)
- Primary completion
- December 2025
- Study completion
- December 2026 (planned)
- Last registry update
- January 2025
- Countries
- Taiwan
Conditions studied: Alopecia Areata
Interventions: Baricitinib
Other trials of Baricitinib (Olumiant)
Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent
A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
- NCT07645430Completed
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.